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Data collected from medical literature indicate that dopaminergic agonists alleviate Restless Legs Syndrome symptoms while 
dopaminergic agonists antagonists aggravate them. Dopaminergic agonists is a physiological regulator of thyroid-stimulating hor-
mone. Dopaminergic agonists infusion diminishes the levels of thyroid hormones, which have the ability to provoke restlessness, 
hyperkinetic states, tremors, and insomnia. Conditions associated with higher levels of thyroid hormones, such as pregnancy or 
hyperthyroidism, have a higher prevalence of Restless Legs Syndrome symptoms. Low iron levels can cause secondary Restless 
Legs Syndrome or aggravate symptoms of primary disease as well as diminish enzymatic activities that are involved in dopaminer-
gic agonists production and the degradation of thyroid hormones. Moreover, as a result of low iron levels, dopaminergic agonists 
diminishes and thyroid hormones increase. Iron therapy improves Restless Legs Syndrome symptoms in iron deprived patients. 
Medical hypothesis. To discuss the theory that thyroid hormones, when not counterbalanced by dopaminergic agonists, may pre-
cipitate the signs and symptoms underpinning Restless Legs Syndrome. The main cause of Restless Legs Syndrome might be an 
imbalance between the dopaminergic agonists system and thyroid hormones. 
KEYWORDS: Restless Legs Syndrome, RLS; RLS pathophysiology; Dopamine; TSH; CYP450. 
Editors Note: This article opens a new section in which experienced authors will contribute a measure of speculative thought on 
apparently unrelated themes in medical practice.
INTRODUCTION 
Dopamine (DA), when diminished, plays an important 
role in the pathophysiology of Restless Legs Syndrome 
(RLS) when decreased DA levels are a primary condition, or 
a secondary condition as is the case when low iron levels have 
been identified. It is known that DA agonists alleviate RLS 
symptoms, and there is medical evidence that DA depresses 
the thyroid axis, which is a concern in certain clinical settings.
 The daily profile of thyroid-stimulating-hormone (TSH) 
levels resembles the daily circadian intensity profile of 
symptoms of an RLS patient. Levels of TSH increase in the 
evening, as does the severity of RLS symptoms. To date, 
DA agonists have been considered to be the best therapy for 
RLS disturbances. In addition, the DA system modulates 
thyroid hormones (TH). One mechanism by which TH is 
modulated by the DA system is through enhancement of 
the biochemical functions of the complex family of the 
cytochrome P450 (CYP450) enzymes. In addition, DA and 
DA agonists inhibit TSH secretion. The CYP450 enzymes 
are heme enzymes (all have iron) and the CPY450 enzyme 
superfamily is important for the biochemical degradation 
of TH. However, low iron levels diminish the quantity 
of CYP450 available to degrade TH. Several drugs that 
alleviate the symptoms of RLS are inducers of CYP450 
activity, as induced CYP450 activity leads to enhanced 
degradation activity, causing TH levels to diminish. 
RLS, also called Ekbom’s syndrome, is a sensorimotor 
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disorder that can be seen in approximately 1% to 15% 
of normal individuals; 5% to 10% of adults in Northern 
European population–based studies report RLS symptoms.1,2 
The prevalence of RLS is increased with pregnancy, uremia, 
anemia, and rheumatoid arthritis; it is more common in 
women than men and its onset can occur at any age.3 It is 
now understood that considerably severe RLS can occur in 
up to 0.5% of children and 1% of adolescents.4 Significant 
variability in the severity of RLS is not uncommon. In the 
most severe cases, RLS may seriously impact a patient’s 
quality of life.1-7
The currently accepted definition of adult RLS from the 
“International Restless Syndrome Study Group (IRLSSG)” 
and the “International Classification of Sleep Disorders, 
second edition (ICSD-2)”, are described below. All four 
features are necessary to make the diagnosis in adults and 
children.1,2,7
1) An urge to move the legs is usually accompanied or 
caused by uncomfortable and unpleasant sensations in 
the legs.
2) The urge to move or unpleasant sensations begin or 
worsen during periods of rest or inactivity, such as lying 
or sitting.
3) The urge to move or unpleasant sensations are partially 
or totally relieved by movements such as walking or 
stretching, as long as the activity continues.
4) The urge to move or unpleasant sensations are worse in 
the evening or night than during the day or only occur in 
the evening or night.
The supportive clinical features of RLS include a positive 
family history of RLS, periodic limb movements during 
sleep, and periodic limb movements during wakefulness. An 
additional supportive clinical feature is the “improvement of 
RLS symptoms with DA therapy”.1,2,7 
IRON LEVELS, TYROSINE HYDROXYLASE, 
CYTHOCROME P450, DA AND TH
Among the associated clinical features of RLS, as stated 
by the IRLSSG, is a serum ferritin level <50 µg/L.7 Ferritin, 
an iron-binding protein is, at low levels, one of the most 
sensitive indicators of iron deficiency. Iron is a cofactor of 
tyrosine hydroxylase, a limiting enzyme in the synthesis 
of DA. Local iron deficiency in the substantia nigra could 
impair dopaminergic receptors or transporters. At the present 
time, there is robust evidence that low iron levels are one of 
the causative factors of RLS or of increasing its severity.8-10 
Diminished DA function has a role in RLS symptoms, as can 
be inferred from the fact that DA agonists are beneficial to 
RLS patients, whereas antagonists are detrimental, and low 
iron levels are a putative cause of decreased DA function.8 
The cytochrome P450 (CYP450) superfamily is another 
enzymatic complex that is down-regulated in response to 
iron scarcity.11 CYP450 is constituted by heme proteins 
and, thus, contains iron.12 In TH metabolism, the CYP450 
complex is very important in the degradation of TH through 
what is called the “Phase 1 elimination of a drug”.13 Drugs 
that inhibit CYP450 activity down-regulate the degradation 
of substances, such as TH, that are substrates of CYP450. 
The opposite occurs with drugs that induce CYP450 
activity.13 The evidence described above allows us to infer 
that not only is iron deficiency a limiting condition for 
tyrosine hydroxylase activity, which is detrimental to RLS 
patients, but it also reduces CYP450 activity. It is important 
to also consider data previously published in the medical 
literature demonstrating that DA modulates TH, that is, 
DA depresses the TH axis.14-16 Because the DA system 
enhances CYP450 activity and TH is a substrate for CYP450 
enzymatic activity, it is possible to infer that one way that the 
DA system can modulate TH is via CYP450: the activation 
of CYP450 down-regulates TH.17 Furthermore, DA and 
DA agonists inhibit TSH secretion.16 CYP450 isoforms are 
expressed in the liver and other peripheral organs, and also 
in glial cells and neurons in the brain18 (Figure 1).
DAILY TSH PROFILE AND CIRCADIAN ASPECTS 
OF RLS SYMPTOMS
In the field of basic sleep science, an analysis of the 
daily TSH profile and its correlation with sleep phase is of 
great relevance. Also relevant is the comparison of the daily 
TSH profile and the propensity to sleep during times of the 
day that are not synchronized with sleep phase timing. The 
normal daily pattern of TSH secretion shows a circadian 
variation; circulating TSH concentrations are low and 
relatively stable during the daytime. TSH levels then begin 
an acrophase in the early evening, with a steep increase 
before sleep onset, and peak at around the beginning of the 
Figure 1 - A diagram showing the abnormal directions that DA and THs 
take under conditions of iron scarcity, and the resulting imbalance between 
DA and THs. Dopamine (DA). Thyroid Hormones (THs). 
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sleep period. In sequence, TSH levels progressively diminish 
throughout the sleep period until they reach their low 
daytime values. The circadian trough of TSH levels normally 
occurs between midday and 6 pm.19 
Sleeping is not impossible out of the sleep phase, but the 
propensity to sleep usually varies significantly during the 
period between 7 am and 11 pm. The greatest propensity to 
sleep occurs in the mid-afternoon, which coincides with the 
circadian trough of TSH levels. The lowest propensity to sleep 
is in the evening during the steep circadian increase in TSH 
levels.20 Notably, the worsening of the symptoms of a typical 
RLS patient also occurs in the evening (fourth criterion of the 
IRLSSG).1,7 The parallel between the evening increase of TSH 
levels and the “worsening RLS symptoms” is of the utmost 
importance when considering the plausibility of the hypothesis 
proposed in this paper. The higher propensity to sleep when 
TSH levels are low, and the lower propensity to sleep when 
TSH levels are increasing could be a mere coincidence; 
however, considering that the effect of TH is to decrease 
the ability to sleep, even resulting in insomnia, and that 
diminished TH cause somnolence,21,22 it is likely that there is 
a causal relationship between TSH levels and RLS (Figure 2).
Analyzing plots of TSH values over a 24-hour period 
and the relationship of the curve to sleep phase or sleep 
propensity can contribute to our understanding certain 
circadian characteristics of the sleep-wake rhythm. These 
characteristics include the propensity to sleep, sleep itself, 
arousabilty from sleep, and voluntary or involuntary sleep 
deprivation. It has previously been held that the waveform of 
the daily profile values of TSH is influenced by sleep.19,23,24 
This interpretation might not be totally accurate, as inference 
from the physiological and therapeutics effects of thyroid 
hormones (activity inducers) suggest that TSH levels 
influence sleep and not the contrary. In other words, the 
daily circadian waveform of thyrotropin could well be titled 
“The Thyroid Axis and Sleep”, instead of “Sleep and the 
Thyroid Axis”.The effects of TH are more likely to promote 
sleeplessness rather than sleepiness.21,22 
Also relevant to this line of reasoning is the fact that the 
greatest propensity for sleep occurs during the circadian 
trough of the TSH waveform, from mid- to late-afternoon 
20
. Could this heightened “propensity-for-sleep,” rather than 
sleep itself, be responsible for the declining TSH values and 
the circadian trough of TSH? Could “sleep propensity” be a 
modulating condition of TSH? The possibility that the “low 
propensity for sleep” 20 associated with the early evening is 
responsible for the steep increase in TSH levels (TSH surge) 
is also unlikely. Could “propensity-to-sleep” be considered a 
“function” that possibly modulates other functions? 
The idea that sleep deprivation relieves the inhibitory 
effects of sleep on TSH levels 23 is not correct. A more 
reasonable interpretation of the relationship between TSH 
level and sleep is that sleep deprivation is made possible by 
the elevation of TH, not the reverse. As sleep deprivation is 
an abnormal condition, contrary to sleep-wake homeostasis, 
it is logical to infer that some function (or functions) must 
be executed to enable the curtailment of sleep. Considering 
the physiological and pharmacological profiles of TH, they 
can be mainly considered as hormones inhibitors of sleep. 
In this light, TSH levels are important in modulating sleep 
propensity. During the biological day, the propensity for 
sleep is low in the late morning,20 a period when TSH levels 
are higher than during late afternoon. The fact that it is much 
more difficult to maintain wakefulness in the second half 
of the biological night,20 when TSH levels are lower than 
in the first half, needs to be factored into any understanding 
of these phenomena. From clinical RLS grounds it is well 
known that the best period for an RLS patient to sleep is in 
the early morning, which coincides with lower levels of TSH. 
It is also well known from clinical and pharmacology studies 
that sleep attack is a concerning side effect of DA therapy.3,5 
A reasonable explanation for this fact is that DA therapy 
depresses TH,16 which are responsible for maintaining the 
alertness of wakefulness. It is equally important to analyze 
the interaction between TSH levels and sleep during the sleep 
phase. After sleep onset, TSH levels remain high during the 
night compared to daytime values. After reaching peak around 
sleep onset, TSH levels progressively decrease throughout 
the sleep phase towards low daytime values.19 In the case of 
sleep deprivation, this nocturnal decline is not observed.23 
Apparently there is a paradox with regard to the fact that 
TSH levels are higher during the sleep phase than during 
wakefulness, but this is likely not without explanation: at the 
onset of sleep, the circadian rhythm imposes its sleep drive 
and the individual starts sleeping; during sleep there is a 
dramatic decline in the sleeping person’s alertness, but there 
remains an arousability condition inherent to the sleep state, 
critical for survival purposes. The physiological and clinical 
profiles of TH suggest that TH comprise the putative system 
that permits arousability from the sleep state. 
From clinical sett ings,  i t  is  well  known that 
hypothyroidism causes a low level of alertness and 
somnolence in patients. While the arousability condition 
inherent to the sleep state may involve additional systems, 
robust evidence in medical science leads us to posit that 
TH is very important to this biological phenomenon. The 
reason that TSH levels are depressed during wakefulness 
compared to the sleep phase can be logically explained by 
the following: the wakefulness state inherently maintains 
higher alertness, driven by circadian rhythmicity; thus 
necessitating lower TH levels. Some TH is needed, however, 
to prevent sleep from transforming into a coma state. It is 
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of interest to mention that myxedema coma represents the 
extreme manifestation of severe hypothyroidism.22 
TSH LEVELS, DEEP NREM SLEEP, AND THE AL-
PHA SLOW WAVE INDEX OF AROUSAL
One important study used concomitant 10-minute 
TSH blood samplings and polysomnography in young 
volunteers.25 During normal sleep and recovery sleep 
after sleep deprivation, the descending slopes of TSH 
concentrations and the episodes of slow wave sleep (SWS) 
were selectively associated with each other. Conclusions 
drawn by the authors were that SWS appeared to be a key 
factor in the inhibitory effect of sleep on TSH secretion. 
However, the interpretation of the results of this work is 
questionable. There is no evidence that SWS inhibits TSH 
secretion, and the assumption that the decline of TSH 
values is a permissive condition for the occurrence of SWS 
seems more logical. A study examining the association 
between EEG spectral power and concomitant TSH 
values demonstrated a negative correlation between TSH 
fluctuations and SWS. 19 This latter study concluded that the 
descending slopes of TSH levels help enable sleep to reach 
deep NREM stages. It was also demonstrated that the alpha 
slow wave index, an index of arousal derived from EEG, 
coincided with elevations of TSH concentrations.26 The 
overall nocturnal profile of TSH reflected the importance 
of high levels of TSH as an arousability factor. The higher 
the TSH profile, the higher the arousal index. Additionally, 
Brabant et al.19 and Gronfier et al.26 showed that TH does 
have a role in sleep modulation (Figure 2).
SUMMARY OF THE INTERACTIONS BETWEEN 
DA, TH AND RLS.
TH levels follow DA levels14-16 Thus, the depressing 
effects of DA on TH are a concern in certain clinical 
settings.27-29 Thyroid-releasing hormone (TRH) regulates 
TSH synthesis by stimulating the transcription and 
translation of the TSH β-subunit gene; dopamine inhibits this 
process.30 Anti-DA drugs such as metoclopramide aggravate 
the symptoms of RLS,17 while DA agonists diminish 
RLS symptoms.31-35 Reduced levels of iron diminish the 
DA system, which in turn aggravates RLS.10-12, 22 TH axis 
heightens during sleep deprivation, as demonstrated in 
voluntary sleep deprivation. 23 Sleep deprivation, in turn, 
is well known to aggravate RLS symptoms.5 Some of the 
effects of increased TH, such as hyperthyroidism, resemble 
some symptoms of RLS patients.21, 22 Opioids, the first class 
of drugs used to treat RLS,3, 5 are also known to depress 
the TH axis.36,37 Some drugs that are effective against RLS 
symptoms, such as carbamazepine, phenobarbital, valproate, 
and primidone are inducers of CYP450 enzyme activity.38 
Selective serotonin reuptake inhibitors, neuroleptics, 
tricyclic antidepressants, and antihistamines are all CYP450 
inhibitors,39 and they all worsen the symptoms of an 
RLS patient.3,5 It is unlikely that the facts above be mere 
coincidence (Figure 3).
 
RLS IN PREGNANCY
RLS is more common in pregnant women than in non-
pregnant women,5 and endocrinological studies in pregnancy 
have revealed that TH are up regulated during pregnancy.40 
This phenomenon supports the hypothesis proposed here, 
although it is possible that other conditions might be 
involved in the greater prevalence of RLS during pregnancy. 
A recent work showed elevated estradiol plasma levels in 
RLS pregnant women.41 The authors raised the possibility 
Figure 2 - depicts the proposed relationship between TSH levels with 
sleep propensity and sleep. Modified from Pannain and Van Cauter 24: 
“Mean 24-hour profile of plasma TSH during a 53-hour period including 8 
hours of nocturnal sleep (black bar), 28 hours of continuous wakefulness 
(nocturnal hours: white bar), and 8 hours of daytime sleep (black bar at the 
right). Subjects were young healthy men. The shadow area corresponds to 
normal 24-hour conditions. The vertical bar at each time point represents 
the standard error of the mean (SEM) ...” (Pannain S, Van Cauter E. Sleep 
Medicine Clinics 2007; 2: 147-159).
Figure 3 - A diagram showing the effects of CYP450 inducers or inhibitors 
on TH metabolism and the final results of these pharmacological actions 
on T4 and T3 levels. Thyroid hormones (THs); Thyroxine (T4); Triiodo-
thyronine (T3).
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that the augmented estradiol could be a causative factor for 
RLS. However, as there is no evidence of elevated estradiol 
in non-pregnant RLS patients, it must be inferred that the 
causality of elevated estradiol on RLS in pregnancy, is, at 
best, indirect. The parallel between the augmented hormones 
TH and estradiol in pregnancy deserves comment. One 
hormonal effect of estradiol is to increase levels of TH.42 
Thus, one possible cause of higher TH levels in pregnancy 
is the higher levels of estradiol, which suggests that estradiol 
may indirectly cause symptoms of RLS by increasing TH. If 
these augmented TH levels are not counterbalanced by the 
DA system, RLS would appear. It is known that estradiol is 
a CYP450 inhibitor, and it also is a condition for the thyroid 
binding globulin to increase.43,44 
HYPERTHYROIDISM AND RLS SYMPTOMS
An interesting case report from Tan and colleagues 
(2004) illustrates the correlation between TH levels and low 
iron levels. A hypothyroid patient with low serum ferritin 
treated with L-thyroxine developed signs and symptoms of 
RLS. Upon challenge and withdrawal of L-thyroxine, there 
was a significant change in the International Restless Legs 
Syndrome Study Group severity score (26/40 to 6/40), the 
periodic limb movements in sleep (PLMS) index (20/hour 
to 10/hour), the number of arousals due to PMLS (59 to 
22), sleep efficiency (74 to 85%), and other biochemical 
parameters 45. As many patients with normal iron levels 
have RLS, one cannot assume that elevated TH and low 
iron levels are the main dysregulations that cause RLS. It 
is, however, possible to infer that this abnormal correlation 
precipitates or aggravates RLS symptoms. L-thyroxine is 
usually administered to hypothyroid patients in the morning, 
which essentially decouples TH levels from the circadian 
biological clock. Therefore, it is not always possible to 
observe the fourth diagnostic criterion of the IRLSSG ( 
worsening of symptoms in the evening and night ).
The greater prevalence of RLS in patients with 
hyperthyroidism over healthy subjects could represent the 
ultimate proof of the importance of TH on the genesis of 
RLS. This assumption might not be that straightforward 
since there are several factors to be considered. For example, 
one must also take into account the modulation of TH by 
the DA system, which cannot be assumed to always be 
impaired. Based on the data we gathered, it is reasonable to 
conclude that the balance between TH and the DA system is 
what counts most. It is their relative values, one in relation 
to another, that are important. 
Despite the dearth of studies on concomitant 
hyperthyroidism and RLS, an important study by Tan 
and colleagues46 emphatically demonstrated that a close 
relationship between hyperthyroidism and RLS symptoms 
does exist. This study examined 125 hyperthyroid patients, 
21 hypothyroid patients, and 434 normal subjects (control 
group). None of the thyroid patients were diagnosed as 
having RLS as defined by the IRLSSG,7 that is, no patients 
met all four criteria for the RLS diagnosis. The authors of the 
study also found that RLS has a low prevalence in Singapore 
where the study took place, as only one subject amongst the 
434 subjects of the control group fulfilled all the criteria for 
diagnosis of RLS (0.2%). Although any case of RLS has been 
found amongst the hyperthyroid patients, the authors observed 
RLS-like symptoms corresponding to the three criteria of the 
IRLSSG in a significant number of the patients. In normal 
subjects, 4/434 (0.9%) met the first three diagnostic criteria 
of RLS, as did 1/21 hypothyroid patients (4.8%), and 11/125 
hyperthyroid patients (8.8%).46 These numbers are significant 
as they seem to substantiate the claim that elevated TH is an 
inciting condition for RLS-like symptoms. 
In accordance with the hypothesis dealt with in this 
paper, it is these authors’ belief that the fourth criterion that 
defines the RLS diagnosis is a consequence of the circadian 
increase of the TH axis in the evening. In Graves’ disease, 
the thyroid gland is dysregulated and TH levels do not follow 
the circadian TH rhythm of a typical normal subject.47
One can assume that a hyperthyroid patient presenting 
with three of the four criteria46 that define the disease might 
not have the disease but rather only symptoms of it. The 
results from the treatment of the hyperthyroid patients46 
were noteworthy. Four patients among the 12 with RLS-like 
symptoms reported complete resolution of their complaints 
(33%): three hyperthyroid to euthyroid, and one hypothyroid 
to euthyroid. The others reported some improvement in 
their symptoms.46 Only these results, pointed out by TAN 
and colleagues are significant per se. However, 4 out of 
11 patients who were hyperthyroid at the beginning of the 
treatment and reported some improvement after treatment, 
were still biochemically hyperthyroid when the results of 
the treatment were tabulated. Logic permits us to suppose 
that the results of the treatment would have even been better 
if the conclusions about the treatment had been drawn after 
these four hyperthyroid patients had become euthyroid. 
Moreover, elevated TH is not the only factor that can cause 
RLS, but it is the inciting condition for the syndrome, not the 
syndrome on its own. Concerning the relationship between 
the DA system and thyroid status, the reader is encouraged 
to review the work of Strawn JR and colleagues.48
FINAL REMARKS 
The RLS augmentation phenomenon, which is a concern 
when treating a patient with DA agonists,3,5 could be partly 
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explained by the common biofeedback mechanism that 
occurs when a hormone is being artificially diminished. 
Tolerance for a drug that is both an inducer and substrate 
of CYP450 could also explain some of the characteristics 
of the augmentation phenomenon. For example, tolerance 
to carbamazepine,49 which is also an effective treatment 
for RLS, is common. This drug, an inducer and substrate 
of CYP450, slowly causes tolerance because the induction 
of CYP also increases the speed with which carbamazepine 
itself is metabolized, rendering it less effective at inducing 
metabolism of TH. Notwithstanding, we do agree that 
there is not, as yet, a cognizance of the real causes of the 
augmentation phenomenon. Thus, it is difficult to explain 
why RLS symptoms start earlier in the day after the RLS 
augmentation phenomenon has been initiated. 
RLS is more common in older patients who are known 
to have a slower metabolism of TH compared to younger 
subjects. Hypothyroidism in older patients usually requires 
lower doses of thyroid hormone replacement.50 In light of 
the hypothesis of this work, there is a reasonable possibility 
that the slower metabolism of TH in the older subjects makes 
them more susceptible to RLS. In addition, subclinical 
hyperthyroidism is also more common (2%) in elderly 
subjects.50 
“Growing pains” are common in childhood RLS,51 and 
some adult patients also complain of pain concomitant 
with other classical symptoms of RLS in the legs.3,5 A very 
important study by Ondo and colleagues (2000) demonstrated 
that the dopaminergic system in rats sends long projections 
from the midbrain into the spinal cord, which influences the 
gating of peripheral nociceptive input.52 With the profuse data 
demonstrating the tight interactions between TH and DA, it 
seems plausible that TH mediates these nociceptive inputs and 
that pain ensues when these inputs are not counterbalanced by 
DA. Growing pains occur mainly in the evening or night when 
TH levels are higher; they usually do not occur during the day 
when TH levels are lower. 
Rye and Freeman reported that DA synthesis, release, 
and signaling peak early during the active period and reach 
their nadir in the sleep phase.53 DA allows the gating of 
inputs via alteration of membrane properties and specific 
ion conductances.54 Rye and Freeman explain that the 
physiological effects of the DA system are best characterized 
as “neuromodulatory,” rather than eliciting excitatory or 
inhibitory postsynaptic potentials.53 From the considerations 
about RLS clinical and physiopathology issues described 
above, it is possible to infer that the DA system also has a 
hormonal modulatory effect on TH. 
The hypothesis we presented refers only to primary 
RLS cases and those that are secondary to iron deficiency 
and pregnancy, which constitute the great majority of RLS 
patients. For these clinical situations, we have found strong 
evidence to support the hypothesis. We did not attempt to 
theorize about the pathophysiology of other secondary cases 
of RLS because we believe that doing so would be only 
speculation, in light of the few existent data on secondary 
RLS cases at this moment. We have also chosen not to address 
“Periodic Limb Movement in Sleep” for the same reason. 
This theoretical study attempts to establish a unified 
theory for RLS pathophysiology through a review of the 
current knowledge on this topic. A hypothesis is rendered 
null and void if it is not supported by experimentation 
to validate it. Studies focusing on the TH axis and DA 
system in patients suffering from RLS might teach us more 
about this very serious human disease. A more detailed 
understanding of the importance of the cytochrome P450 
enzyme system in RLS is warranted, as are studies of the 
genetics of the cytochrome P450 system. Moreover, iron 
deprivation might not be a concern restricted to RLS. 
Another issue raised by this paper is whether deviations 
of the normality of TH axis and DA system interaction 
might actually influence the quality of sleep in sleep 
disturbances other than RLS. Thus, RLS could be considered 
a paradigmatic disease for other sleep disturbances. 
We are much indebted to Dr Arthur S. Walters, Professor 
of Neurology Vanderbilt School of Medicine, Nashville, 
Tenesee, USA, for help criticism of the manuscript and 
kindly attention.
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